Celeris Therapeutics

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

AI-enabled drug design

This company develops generative machine learning platforms to design and optimise small-molecule drug candidates for pharmaceutical and biotechnology partners.

Molecular Glue Labs

This company develops artificial intelligence software and infrastructure to design small-molecule drugs that reprogram protein networks to treat previously untreatable diseases.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Ternary Therapeutics

This company develops an artificial intelligence platform to design molecular glue therapeutics for healthcare providers and pharmaceutical partners to treat complex diseases.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Aqemia

This company develops a drug discovery platform using physics-based algorithms and artificial intelligence for pharmaceutical and biotechnology organisations.